Microparticles in deep venous thrombosis, antiphospholipid syndrome and Factor V Leiden. 2009

M C Flores-Nascimento, and M P Beltrame, and E V De Paula, and S L Montalvão, and F G Pereira, and F L A Orsi, and I Lorand-Metze, and J M Annichino-Bizzacchi
Hematology-Hemotherapy Center, State University of Campinas, Campinas, SP, Brazil. flores_mariane@yahoo.com.br

Microparticles (MPs) are blebs released from cellular surfaces during activation/apoptosis. They are procoagulant, pro-inflammatory and could contribute to pathogenesis of deep venous thrombosis (DVT). This study compared the number, cellular origin and procoagulant activity of MPs on DVT patients in different clinical situations: at diagnosis (n = 9, 5F/4M; mean age = 41.11), 1-3 years after warfarin withdrawal (n = 10, 7F/3M; mean age = 32.90), associated to antiphospholipid syndrome (APS; n = 11, 9F/2M; mean age = 33.82), or asymptomatic carriers of Factor V Leiden (FVL; n = 7, 7F/0M; mean age = 34.00) vs healthy controls (CTR). The quantification and characterization were performed by flow cytometry using CD235, CD61, CD45, CD31, CD14, CD45, anti-TF and Annexin V. The plasmatic procoagulant activity was investigated by prothrombin fragment 1 + 2 (F1 + 2) determination. The MPs procoagulant activity was analyzed by D-dimer (DD2) and Thrombin Generation Test (TGT) on a healthy pool of plasmas adjusted or not by their number (10,000 MPs). The MPs percentages were not different between the groups, but absolute number was increased in patients 1-3 years after warfarin withdrawal vs CTR (P = 0.02). There was no difference of the MPs cellular origin comparing patients to controls. TGT using 10,000 MPs was lower on these patients (P = 0.01). APS patients showed a reduction of plasmatic procoagulant activity (P = 0.004), but they were under warfarin therapy. DD2 in the presence of MPs, independently of its number, was higher in patients with DVT at diagnosis (P < 0.0001). MPs of patients with spontaneous DVT at diagnosis can promote coagulation activation demonstrated by increased DD2. Even the increased MPs from patients 1-3 years after thrombotic episode generated lower amount of thrombin, they can have a protective effect by activation of Protein C anticoagulant pathway.

UI MeSH Term Description Entries
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008297 Male Males
D010316 Particle Size Relating to the size of solids. Particle Sizes,Size, Particle,Sizes, Particle
D001780 Blood Coagulation Tests Laboratory tests for evaluating the individual's clotting mechanism. Coagulation Tests, Blood,Tests, Blood Coagulation,Blood Coagulation Test,Coagulation Test, Blood,Test, Blood Coagulation
D005165 Factor V Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor V accomplishes this by forming a complex with factor Xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor V leads to Owren's disease. Coagulation Factor V,Proaccelerin,AC Globulin,Blood Coagulation Factor V,Factor 5,Factor Five,Factor Pi,Factor V, Coagulation
D005260 Female Females
D005338 Fibrin Fibrinogen Degradation Products Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis. Antithrombin VI,Fibrin Degradation Product,Fibrin Degradation Products,Fibrin Fibrinogen Split Products,Degradation Product, Fibrin,Degradation Products, Fibrin,Product, Fibrin Degradation
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M C Flores-Nascimento, and M P Beltrame, and E V De Paula, and S L Montalvão, and F G Pereira, and F L A Orsi, and I Lorand-Metze, and J M Annichino-Bizzacchi
January 2003, Clinical laboratory science : journal of the American Society for Medical Technology,
M C Flores-Nascimento, and M P Beltrame, and E V De Paula, and S L Montalvão, and F G Pereira, and F L A Orsi, and I Lorand-Metze, and J M Annichino-Bizzacchi
January 2000, Joint bone spine,
M C Flores-Nascimento, and M P Beltrame, and E V De Paula, and S L Montalvão, and F G Pereira, and F L A Orsi, and I Lorand-Metze, and J M Annichino-Bizzacchi
September 2006, Saudi medical journal,
M C Flores-Nascimento, and M P Beltrame, and E V De Paula, and S L Montalvão, and F G Pereira, and F L A Orsi, and I Lorand-Metze, and J M Annichino-Bizzacchi
October 2004, Revista espanola de cardiologia,
M C Flores-Nascimento, and M P Beltrame, and E V De Paula, and S L Montalvão, and F G Pereira, and F L A Orsi, and I Lorand-Metze, and J M Annichino-Bizzacchi
January 2006, Revista de neurologia,
M C Flores-Nascimento, and M P Beltrame, and E V De Paula, and S L Montalvão, and F G Pereira, and F L A Orsi, and I Lorand-Metze, and J M Annichino-Bizzacchi
January 1995, Lancet (London, England),
M C Flores-Nascimento, and M P Beltrame, and E V De Paula, and S L Montalvão, and F G Pereira, and F L A Orsi, and I Lorand-Metze, and J M Annichino-Bizzacchi
January 1995, Lancet (London, England),
M C Flores-Nascimento, and M P Beltrame, and E V De Paula, and S L Montalvão, and F G Pereira, and F L A Orsi, and I Lorand-Metze, and J M Annichino-Bizzacchi
January 1995, Lancet (London, England),
M C Flores-Nascimento, and M P Beltrame, and E V De Paula, and S L Montalvão, and F G Pereira, and F L A Orsi, and I Lorand-Metze, and J M Annichino-Bizzacchi
January 2002, Zhonghua yi xue za zhi,
M C Flores-Nascimento, and M P Beltrame, and E V De Paula, and S L Montalvão, and F G Pereira, and F L A Orsi, and I Lorand-Metze, and J M Annichino-Bizzacchi
October 1996, Stroke,
Copied contents to your clipboard!